Mutations in non-structural 5A and rapid viral response to pegylated interferon-α-2b plus ribavirin therapy are associated with therapeutic efficacy in patients with genotype 1b chronic hepatitis C

International Journal of Molecular Medicine

Volumn 30, Issue 5, 2012, Pages 1048-1052

  Yano, Yoshihiko ^a   Seo, Yasushi ^a   Miki, Akira ^a   Saito, Masaya ^a   Kato, Hirotaka ^b   Hamano, Ken Ichi ^c   Oya, Manabu ^d   Ouchi, Sachiko ^e,f   Fujisawa, Takashi ^f   Yamada, Hajime ^g   Yamashita, Yukimasa ^h   Tani, Satoshi ⁱ   Hirohata, Shigeya ^j   Yoon, Seitetsu ^j   Kitajima, Naoto ^k   Kitagaki, Kazunari ^l   Kawara, Akira ^m   Nakashima, Takatoshi ⁿ   Yu, Hosai ^o   Maeda, Tetsuo ^p   Azuma, Takeshi ^a   El Shamy, Ahmed ^a   Hotta, Hak ^a   Hayashi, Yoshitake ^a   more..

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Kato Clinic   (Japan)

^c Hamano Clinic   (Japan)

^d Shin Suma Hospital   (Japan)

^e Steel Memorial Hirohata Hospital   (Japan)

^f Division of Internal Medicine   (Japan)

^g Shinko Hospital   (Japan)

^h KOBE CITY MEDICAL CENTER WEST HOSPITAL   (Japan)

ⁱ Konan Hospital   (Japan)

^j Department of Gastroenterology   (Japan)

^k Kasai City Hospital   (Japan)

^l Konan Hospital Foundation Rokko Island Hospital   (Japan)

^m Kawara Clinic   (Japan)

ⁿ Akashi Medical Center   (Japan)

^o Graduate School of Health Sciences   (Japan)

^p Kawasaki Hospital   (Japan)

more..

Author keywords

Chronic hepatitis C; Non structural 5A; Pegylated IFN and ribavirin therapy

Indexed keywords

ALANINE AMINOTRANSFERASE; NONSTRUCTURAL PROTEIN 5A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BODY MASS; DRUG EFFICACY; FEMALE; GENE MUTATION; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; SUSTAINED VIRAL RESPONSE; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD;

AGED; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; PATIENT COMPLIANCE; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; SEQUENCE ANALYSIS, DNA; TREATMENT OUTCOME; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84866624182     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2012.1093     Document Type: Article

References (28)

1. Seeff LB: Natural history of chronic hepatitis C. Hepatology 36 (Suppl 1): S35-S46, 2002.
2. Lavanchy D: The global burden of hepatitis C. Liver Int 29: 74-81, 2009.
3. Marcellin P: Hepatitis B and hepatitis C in 2009. Liver Int 29: 1-8, 2009.
4. Enomoto N, Sakuma I, Asahina Y, et al: Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 334: 77-81, 1996. (Pubitemid 26017933)
5. Enomoto N, Sakuma I, Asahina Y, et al: Comparison of full length sequences of interferon-sensitive and resistant hepatitis C virus 1b: sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. J Clin Invest 96: 224-230, 1995.
6. El-Shamy A, Nagano-Fujii M, Sasase N, Imoto S, Kim SR and Hotta H: Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapy. Hepatology 48: 38-47, 2008. (Pubitemid 351975529)
7. Kumthip K, Pantip C, Chusri P, et al: Correlation between mutations in the core and NS5A genes of hepatitis C virus genotypes 1a, 1b, 3a, 3b, 6f and the response to pegylated interferon and ribavirin combination therapy. J Viral Hepat 18: e117-e125, 2011.
8. Manns MP, McHutchison JG, Gordon SC, et al: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358: 958-965, 2001. (Pubitemid 32913521)
9. Fried MW, Shiffman ML, Reddy KR, et al: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347: 975-982, 2002.
10. Hadziyannis SJ, Sette H Jr, Morgan TR, et al: Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140: 346-355, 2004.
11. Yu ML, Dai CY, Huang JF, et al: Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology 47: 1884-1893, 2008.
12. Yu JW, Wang GQ, Sun LJ, Li XG and Li SC: Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin. J Gastroenterol Hepatol 22: 832-836, 2007.
13. Jafferbhoy H, Miller MH, El Wahed Z and Dillon JF: Pre-treatment prediction of response to pegylated-interferon plus ribavarin for chronic hepatitis C using RVR. J Hepatol 55: 1162-1164, 2011.
14. Tanioka D, Iwasaki Y, Araki Y, et al: Factors associated with adherence to combination therapy of interferon and ribavirin for patients with chronic hepatitis C: importance of patient's motivation and physician's treatment experience. Liver Int 29: 721-729, 2009.
15. Chung RT, Monto A, Dienstag JL and Kaplan LM: Mutations in the NS5A region do not predict interferon-responsiveness in American patients infected with genotype 1b hepatitis C virus. J Med Virol 58: 353-358, 1999. (Pubitemid 29326048)
16. Zeuzem S, Lee JH and Roth WK: Mutations in the nonstructural 5A gene of European hepatitis C virus isolates and response to interferon alfa. Hepatology 25: 740-744, 1997. (Pubitemid 27106463)
17. Paterson M, Laxton CD, Thomas HC, Ackrill AM and Foster GR: Hepatitis C virus NS5A protein inhibits interferon antiviral activity, but the effects do not correlate with clinical response. Gastroenterology 117: 1187-1197, 1999. (Pubitemid 29512679)
18. Torres-Puente M, Cuevas JM, Jimenez-Hernandez N, et al: Hepatitis C virus and the controversial role of the interferon sensitivity determining region in the response to interferon treatment. J Med Virol 80: 247-253, 2008.
19. Shen C, Hu T, Shen L, Gao L, Xie W and Zhang J: Mutations in ISDR of NS5A gene influence interferon efficacy in Chinese patients with chronic hepatitis C virus genotype 1b infection. J Gastroenterol Hepatol 22: 1898-1903, 2007. (Pubitemid 47525050)
20. Hung CH, Lee CM, Lu SN, et al: Mutations in the NS5A and E2-PePHD region of hepatitis C virus type 1b and correlation with the response to combination therapy with interferon and ribavirin. J Viral Hepat 10: 87-94, 2003. (Pubitemid 36359845)
21. Pascu M, Martus P, Höhne M, et al: Sustained virological response in hepatitis C virus type 1b infected patients is predicted by the number of mutations within the NS5A ISDR: a meta-analysis focused on geographical differences. Gut 53: 1345-1351, 2004. (Pubitemid 39120125)
22. Gale MJ, Korth MJ, Tang NM, et al: Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology 30: 217-227, 1997. (Pubitemid 27211852)
23. Gale MJ, Korth MJ and Katze MG: Repression of the PKR protein kinase by the hepatitis C virus NS5A protein: a potential mechanism of interferon resistance. Clin Diagn Virol 10: 157-162, 1998. (Pubitemid 28399034)
24. Hofmann WP, Zeuzem S and Sarrazin C: Hepatitis C virus-related resistance mechanisms to interferon alpha-based antiviral therapy. J Clin Virol 32: 86-91, 2005. (Pubitemid 40093958)
25. Gervain J, Czibula A, Simon J and Kalmar T: Structural analysis of the PKR-binding region of HCV 1b samples from patients with chronic hepatitis C and the correlation with IFN-sensitivity. Orv Hetil 144: 1179-1184, 2003 (In Hungarian).
26. Tanaka Y, Nishida N, Sugiyama M, et al: Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 41: 1105-1109, 2009.
27. Asselah T, Benhamou Y and Marcellin P: Protease and polymerase inhibitors for the treatment of hepatitis C. Liver Int 29: 57-67, 2009.
28. Forestier N and Zeuzem S: Triple therapy with telaprevir: results in hepatitis C virus-genotype 1 infected relapsers and non-responders. Liver Int 32: 44-50, 2012.